Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Rasche, Leo, Kortüm, K. Martin, Danhof, Sophia, Hudecek, Michael, Einsele, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793717/
https://www.ncbi.nlm.nih.gov/pubmed/33424871
http://dx.doi.org/10.3389/fimmu.2020.620312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793717/
https://www.ncbi.nlm.nih.gov/pubmed/33424871
http://dx.doi.org/10.3389/fimmu.2020.620312

Ejemplares similares